Small molecule HDAC inhibitors are already used in the clinic to treat cancer and hematological disorders,77 and preclinical research with SCFA HDAC inhibitors demonstrates significant potential in epigenetic treatment of neurological conditions.26,101 Epigenetic regulation of host–microbiota interactions by utilizing epigenomic-targeting drugs has been suggested by Alenghat and Artis.74 Here, HDAC9 is linked to hematologic disorder.